Halozyme Therapeutics (HALO) Revenue (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Revenue data on file, last reported at $376.7 million in Q1 2026.

• On a quarterly basis, Revenue rose 42.23% year-over-year to $376.7 million in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 39.12% increase from a year earlier, with the FY2025 full-year figure at $1.4 billion, up 37.55% from the prior year.
• Revenue for Q1 2026 stood at $376.7 million, down from $451.8 million in the prior quarter.
• Over the last five years, Revenue for HALO reached as high as $451.8 million in Q4 2025 and fell as low as $117.3 million in Q1 2022.
• Historically, Revenue has averaged $251.6 million across 5 years, with a median of $230.0 million in 2023.
• Across the five-year window, Revenue soared 80.42% in 2022 and rose 3.38% in 2023, its largest moves.
• Year by year, Revenue stood at $181.5 million in 2022, then increased by 26.75% to $230.0 million in 2023, then grew by 29.55% to $298.0 million in 2024, then surged by 51.6% to $451.8 million in 2025, then fell by 16.61% to $376.7 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $376.7 million in Q1 2026, $451.8 million in Q4 2025, and $354.3 million in Q3 2025.